🇺🇸 FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10106610

Antibodies comprising chimeric constant domains

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10106616

Antagonist antibodies to human prolactin receptor (PRLR)

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10081670

Human antibodies to Ebola virus glycoprotein

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10076571

Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein con

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10077311

Human antibodies to GFR alpha3 and methods of reducing pain associated with GFR alpha3-rel

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10072086

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10070631

Rodents having a humanized TMPRSS gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10072076

Human antibodies to NAv1.7

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10070632

Rodents having a humanized TMPRSS gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10066017

Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagon

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10059771

Methods for treating nasal polyposis by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10047160

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10047152

Human antibodies to fel D1 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10047153

Human antibodies to Fel d1 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023642

Anti-PDGFR-beta antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023641

Anti-TIE2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023644

Antigen-binding proteins that activate the leptin receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023654

Anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023916

Markers of tumor cell response to anti-cancer therapy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10015953

Non-human animals having a humanized cluster of differentiation 47 gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10011647

IL-33 antagonists and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10005834

Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10000564

Methods of treating an inflammatory condition or sensitivity to an allergen with anti-IL-3

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9987500

Human antibodies to PD-1

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted